Aptamers Engineered Nanocarriers for Cancer Therapy 2023
DOI: 10.1016/b978-0-323-85881-6.00015-4
|View full text |Cite
|
Sign up to set email alerts
|

Aptamer-functionalized micelles for targeted cancer therapy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 47 publications
0
2
0
Order By: Relevance
“…Furthermore, their biocompatibility and ability to incorporate various therapeutic agents make micelles versatile carriers, allowing for the co-delivery of multiple drugs [65] or imaging agents [66], enhancing therapeutic efficacy [63], and personalized medicine strategies [67]. Hence, the assembly of aptamer-micelle conjugates demonstrates significant promise in recognizing cancer cells and has potential applications for in vivo drug delivery [68].…”
Section: Aptamer-micelle Conjugationmentioning
confidence: 99%
See 1 more Smart Citation
“…Furthermore, their biocompatibility and ability to incorporate various therapeutic agents make micelles versatile carriers, allowing for the co-delivery of multiple drugs [65] or imaging agents [66], enhancing therapeutic efficacy [63], and personalized medicine strategies [67]. Hence, the assembly of aptamer-micelle conjugates demonstrates significant promise in recognizing cancer cells and has potential applications for in vivo drug delivery [68].…”
Section: Aptamer-micelle Conjugationmentioning
confidence: 99%
“…The micelle incorporates a targeting aptamer, with the aim of minimizing the therapeutic dosage and reducing off-target effects [68]. The dual redox/pH-sensitive poly (β-amino ester) copolymeric micelles are coupled with the CSRLSLPGSSSKpalmSSS peptide and TA1 aptamer as dual-targeting ligands for synergistic targeting in the 4T1 breast cancer model.…”
Section: Aptamer-micelle Conjugationmentioning
confidence: 99%